ACTIVE

NXTLAB

Financial year 2025 · closed on 31/12/2025
Net result
114 k €
+438.3% YoY
Gross margin
114,6 k €
+357.1% YoY
Equity
1,4 k €
+0.6% YoY

What does NXTLAB do?

NXTLAB is a Private limited company incorporated in 2024. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Roeselare.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 1006.873.757
Incorporation
07/03/2024
Legal form
Private limited company
Registered office
Deltalaan 1
8800 Roeselare · FlandreSee on map
Contributed capital
1 200,00 €
Latest accounts
31/12/2025
Signals
ProfitablePositive cashflowPositive EBITDA
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 2 financial years

20252024
Income statement
Gross margin114,6 k €25,1 k €
EBITDA114,1 k €25,1 k €
Operating result114,1 k €21,2 k €
Net result114 k €21,2 k €
Balance sheet
Equity1,4 k €1,4 k €
Total assets119,2 k €24,4 k €
Cash82,5 k €13,7 k €
Debts117,8 k €23,1 k €
Estimate

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2025 · 12 active · 2 ended

Active mandates

An-Sofie Decavele

Director · since 07 mars 2024 · 0536.745.045

Represented by An-Sofie Decavele

Active
CYTOMICS CONSULTING

Director · since 07 mars 2024 · 0742.547.668

Represented by Geert Martens

Active
DR INGE VAN HAUTE

Director · since 07 mars 2024 · 0825.964.007

Represented by Inge Van Haute

Active
Dr. Vercruysse-Vandenbussche

Director · since 07 mars 2024 · 0898.200.204

Represented by Hilde Vandenbussche

Active
DR.E.DE LAERE

Director · since 07 mars 2024 · 0876.511.992

Represented by Emmanuel De Laere

Active
Elmace

Director · since 07 mars 2024 · 0837.978.941

Represented by Eline Verhoye

Active
Frederik Van Hoecke

Director · since 07 mars 2024 · 0698.935.775

Represented by Frederik Van Hoecke

Active
Hilde Vanpoucke - Apotheker Klinisch Bioloog

Director · since 07 mars 2024 · 0824.739.629

Represented by Hilde Vanpoucke

Active
INPE FARMA

Director · since 07 mars 2024 · 0455.853.082

Represented by Inge De Cuyper

Active
JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG

Director · since 07 mars 2024 · 0824.334.011

Represented by Johan Debrabandere

Active
LabMed DDS

Director · since 07 mars 2024 · 0741.659.921

Represented by Dieter De Smet

Active
SA Artsen

Director · since 07 mars 2024 · 0899.054.002

Represented by Steven Vervaeke

Active

Ended mandates

Frederik Van Hoecke

Director · since 07 mars 2024 · 0698.935.775

Represented by Frederik Van Hoecke

Ended
LabMed DDS

Director · since 07 mars 2024 · 0741.659.921

Represented by Dieter De Smet

Ended
At this address

Other companies at this address

CompanyCBE no.
AddisonActive
1015.428.365
0505.931.808
0723.701.459
0754.940.706
0689.980.004
0742.828.374
0781.379.342
1024.732.249
0775.493.026
0536.693.377
0770.509.404
AZ DELTA-MKAActive
0801.278.594
BloodXpertActive
1016.346.105
0762.948.451
0545.787.128
0742.882.121
Delta LongActive
1015.125.091
0886.898.714
0722.918.333
0722.670.982
Annual accounts

Full financial information

20252024
Type of accountMicro modelMicro model
Start of the financial year01/01/202507/03/2024
Closing of the financial year31/12/202531/12/2024
Length of the financial year12 months10 months
Filing date22/06/202614/07/2025
General meeting20/06/202621/06/2025
Currency of the financial yearEUREUR
NBB quality labelSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

2 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Micro model31/12/202520/06/202622/06/2026DutchPDF
Micro model31/12/202421/06/202514/07/2025DutchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 12 active · 2 ended

Active mandates

An-Sofie Decavele

Director · since 07 mars 2024 · 0536.745.045

Represented by An-Sofie Decavele

Active
CYTOMICS CONSULTING

Director · since 07 mars 2024 · 0742.547.668

Represented by Geert Martens

Active
DR INGE VAN HAUTE

Director · since 07 mars 2024 · 0825.964.007

Represented by Inge Van Haute

Active
Dr. Vercruysse-Vandenbussche

Director · since 07 mars 2024 · 0898.200.204

Represented by Hilde Vandenbussche

Active
DR.E.DE LAERE

Director · since 07 mars 2024 · 0876.511.992

Represented by Emmanuel De Laere

Active
Elmace

Director · since 07 mars 2024 · 0837.978.941

Represented by Eline Verhoye

Active
Frederik Van Hoecke

Director · since 07 mars 2024 · 0698.935.775

Represented by Frederik Van Hoecke

Active
Hilde Vanpoucke - Apotheker Klinisch Bioloog

Director · since 07 mars 2024 · 0824.739.629

Represented by Hilde Vanpoucke

Active
INPE FARMA

Director · since 07 mars 2024 · 0455.853.082

Represented by Inge De Cuyper

Active
JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG

Director · since 07 mars 2024 · 0824.334.011

Represented by Johan Debrabandere

Active
LabMed DDS

Director · since 07 mars 2024 · 0741.659.921

Represented by Dieter De Smet

Active
SA Artsen

Director · since 07 mars 2024 · 0899.054.002

Represented by Steven Vervaeke

Active

Ended mandates

Frederik Van Hoecke

Director · since 07 mars 2024 · 0698.935.775

Represented by Frederik Van Hoecke

Ended
LabMed DDS

Director · since 07 mars 2024 · 0741.659.921

Represented by Dieter De Smet

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Other11/03/2024
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025114 k €
  2. 2024
    Annual accounts 202421,2 k €
  3. 07/03/2024
    IncorporationPrivate limited company